Venus Remedies is developing molecule for breast cancer detection
Apr 28, 2011
Venus Remedies has announced the completion of Phase I and II clinical trials for a molecule that it is developing in order to detect breast cancer.
The VRP 1620 is said to have shown "excellent results" in detecting cancer, according to the Business-Standard.
Venus Remedies is among the top 50 pharmaceutical companies in India, according to its website.
"With this drug detection of breast cancer would be possible even with a simple X-ray using dye and the sensitivities of other detection devices such as colored doppler," said Venus Remedies, the news source reports.
The second part of the trials were held at several institutes throughout India, including the Central India Cancer Institute.
Breast cancer is an illness that knows no borders, with people in almost every country susceptible to the illness. In the U.S., the incidence rate of breast cancer is about one in eight women, according to the American Cancer Society. The ACS also recommends that all women over the age of 40 receive yearly mammograms as a screening tool for detecting tumors.